MedAvail (MDVLQ) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 10, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	6665 Millcreek Dr.
Entity Address, Address Line Two	Unit 1
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5N 5M4
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,746,549
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 48,735	$ 57,936
Restricted cash	62	60
Accounts receivable (net of allowance for doubtful accounts of $39 thousand for June 30, 2021, $40 thousand for December 31, 2020)	1,058	1,520
Inventories	3,171	2,817
Prepaid expenses and other current assets	1,039	1,534
Total current assets	54,065	63,867
Property, plant and equipment, net	4,302	3,795
Right-of-use assets	1,283	1,239
Other assets	214	203
Intangible assets	1,386	227
Total assets	61,250	69,331
Current liabilities:
Accounts payable and accrued liabilities	7,047	4,512
Short-term debt	1,000	2,161
Contract liability	328	275
Current portion of lease obligations	549	665
Total current liabilities	8,924	7,613
Long-term debt, net	9,414	0
Long-term portion of lease obligations	813	651
Total liabilities	19,151	8,264
Commitments and contingencies
Stockholders' deficit:
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,583,734 and 31,816,020 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively)	33	32
Warrants	1,485	2,614
Additional paid-in-capital	215,700	213,624
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(168,191)	(148,275)
Total stockholders' equity	42,099	61,067
Total liabilities and stockholders' equity	$ 61,250	$ 69,331

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 39	$ 40
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	100,000,000	100,000,000
Common shares, issued (in shares)	32,583,734	31,816,020
Common shares, outstanding (in shares)	32,583,734	31,816,020

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Sales:
Total sales	$ 5,030	$ 2,311	$ 9,057	$ 3,723
Cost of sales:
Total cost of sales	4,857	1,865	8,564	3,297
Gross profit	173	446	493	426
Pharmacy operations	2,292	1,116	4,224	2,205
General and administrative	6,646	3,580	13,136	7,080
Selling and marketing	1,497	570	2,878	1,273
Research and development	201	163	369	378
Merger expenses	0	1,283	0	1,283
Operating loss	(10,463)	(6,266)	(20,114)	(11,793)
Other gain (loss), net	38	0	199	8
Interest income	27	7	67	15
Interest expense	(66)	(277)	(68)	(456)
Loss before income taxes	(10,464)	(6,536)	(19,916)	(12,226)
Income tax	0	0	0	0
Net loss	(10,464)	(6,536)	(19,916)	(12,226)
Other comprehensive income (loss):
Foreign currency translation adjustment	0	0	0	(2)
Total comprehensive loss	$ (10,464)	$ (6,536)	$ (19,916)	$ (12,228)
Net loss per share - basic (in USD per share)	$ (0.32)	$ (3.35)	$ (0.61)	$ (6.50)
Net loss per share - diluted (in USD per share)	$ (0.32)	$ (3.35)	$ (0.61)	$ (6.50)
Weighted average shares outstanding - basic (in shares)	32,546,395	1,953,049	32,493,468	1,880,577
Weighted average shares outstanding - diluted (in shares)	32,546,395	1,953,049	32,493,468	1,880,577
Pharmacy and hardware sales
Sales:
Total sales	$ 4,725	$ 2,259	$ 8,506	$ 3,661
Cost of sales:
Total cost of sales	4,679	1,826	8,205	3,211
Service sales
Sales:
Total sales	305	52	551	62
Cost of sales:
Total cost of sales	$ 178	$ 39	$ 359	$ 86

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Common Shares	Warrants	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Temporary equity beginning balance (in shares) at Dec. 31, 2019	[1]	10,500,440
Temporary equity beginning balance at Dec. 31, 2019	[1]	$ 93,484
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of preferred shares (in shares)	[1]	102,777
Issuance of preferred shares	[1]	$ 788
Temporary equity ending balance (in shares) at Jun. 30, 2020	[1]	10,603,217
Temporary equity ending balance at Jun. 30, 2020	[1]	$ 94,272
Balance at beginning of period (in shares) at Dec. 31, 2019			1,504,251
Balance at beginning of period at Dec. 31, 2019			$ 8	$ 698	$ 30,829	$ (121,230)	$ (6,950)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(12,226)				(12,226)
Shares issued for options exercises (in shares)			19,744
Shares issued for options exercises		31			31
Share-based compensation		170			170
Warrants issued		606		617	(11)
Foreign currency translation adjustment		(2)					(2)
Balance at end of period (in shares) at Jun. 30, 2020			1,523,995
Balance at end of period at Jun. 30, 2020			$ 8	1,315	31,019	(133,456)	(6,952)
Total equity and temporary equity at beginning of period at Dec. 31, 2019		(3,161)
Total equity and temporary equity at end of period at Jun. 30, 2020		$ (13,794)
Temporary equity beginning balance (in shares) at Mar. 31, 2020	[1]	10,603,217
Temporary equity beginning balance at Mar. 31, 2020	[1]	$ 94,272
Temporary equity ending balance (in shares) at Jun. 30, 2020	[1]	10,603,217
Temporary equity ending balance at Jun. 30, 2020	[1]	$ 94,272
Balance at beginning of period (in shares) at Mar. 31, 2020			1,521,411
Balance at beginning of period at Mar. 31, 2020			$ 8	1,133	30,929	(126,920)	(6,952)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(6,536)				(6,536)
Shares issued for options exercises (in shares)			2,584
Shares issued for options exercises		4			4
Share-based compensation		86			86
Warrants issued		182
Foreign currency translation adjustment		0
Balance at end of period (in shares) at Jun. 30, 2020			1,523,995
Balance at end of period at Jun. 30, 2020			$ 8	1,315	31,019	(133,456)	(6,952)
Total equity and temporary equity at beginning of period at Mar. 31, 2020		(7,530)
Total equity and temporary equity at end of period at Jun. 30, 2020		$ (13,794)
Temporary equity beginning balance (in shares) at Dec. 31, 2020	[1]	0
Temporary equity beginning balance at Dec. 31, 2020	[1]	$ 0
Temporary equity ending balance (in shares) at Jun. 30, 2021	[1]	0
Temporary equity ending balance at Jun. 30, 2021	[1]	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2020			31,816,020
Balance at beginning of period at Dec. 31, 2020		61,067	$ 32	2,614	213,624	(148,275)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		$ (19,916)				(19,916)
Shares issued for options exercises (in shares)		144,101	144,101
Shares issued for options exercises		$ 241			241
Exercise of warrants (in shares)			623,613
Exercise of warrants		124	$ 1	(1,129)	1,252
Share-based compensation		583			583
Foreign currency translation adjustment		0
Balance at end of period (in shares) at Jun. 30, 2021			32,583,734
Balance at end of period at Jun. 30, 2021		42,099	$ 33	1,485	215,700	(168,191)	(6,928)
Total equity and temporary equity at beginning of period at Dec. 31, 2020		61,067
Total equity and temporary equity at end of period at Jun. 30, 2021		$ 42,099
Temporary equity beginning balance (in shares) at Mar. 31, 2021	[1]	0
Temporary equity beginning balance at Mar. 31, 2021	[1]	$ 0
Temporary equity ending balance (in shares) at Jun. 30, 2021	[1]	0
Temporary equity ending balance at Jun. 30, 2021	[1]	$ 0
Balance at beginning of period (in shares) at Mar. 31, 2021			31,939,898
Balance at beginning of period at Mar. 31, 2021			$ 32	2,579	214,125	(157,727)	(6,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(10,464)				(10,464)
Shares issued for options exercises (in shares)			23,177
Shares issued for options exercises		40			40
Exercise of warrants (in shares)			620,659
Exercise of warrants		119	$ 1	(1,094)	1,212
Share-based compensation		323			323
Foreign currency translation adjustment		0
Balance at end of period (in shares) at Jun. 30, 2021			32,583,734
Balance at end of period at Jun. 30, 2021		42,099	$ 33	$ 1,485	$ 215,700	$ (168,191)	$ (6,928)
Total equity and temporary equity at beginning of period at Mar. 31, 2021		52,081
Total equity and temporary equity at end of period at Jun. 30, 2021		$ 42,099
[1]	$0.001 par value, 10,000,000 shares authorized at June 30, 2021 and December 31, 2020. $0.001 par value, 15,539,330 shares authorized at June 30, 2020.

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders' Equity (Deficit) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]
Redeemable preferred shares, par value (in USD per share)	$ 0.001	$ 0.001
Redeemable preferred shares, authorized (in shares)	10,000,000	10,000,000	15,539,330

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (19,916)	$ (12,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	586	463
Amortization of intangible and leased assets, and debt discount	480	350
Bad debt and other non cash receivables adjustments	21	0
Interest accretion on debt and finance leases	4	473
Unrealized foreign currency (loss) gain	0	(2)
Share-based compensation expense	583	170
Warrant expense	0	158
PPP loan forgiveness gain	(161)	0
Changes in operating assets and liabilities:
Change in accounts receivable	441	(25)
Change in inventory	(893)	(134)
Change in prepaid expenses and other current assets	495	(264)
Change in accounts payable, accrued expenses and other liabilities	2,123	1,113
Change in contract liability	53	119
Change in operating lease liability due to cash payments	(332)	(268)
Net cash used in operating activities	(16,516)	(10,073)
Cash flows from investing activities:
Purchase of property, plant and equipment	(411)	(243)
Payment of security deposits	(11)	(39)
Purchase of intangible assets and other assets	(991)	(20)
Net cash used in investing activities	(1,413)	(302)
Cash flows from financing activities:
Issuance of common shares upon exercise of options and warrants	365	31
Issuance of preferred shares	0	788
Proceeds from debt	10,000	8,094
Payment of debt issuance costs	(604)	(64)
Repayment of debt	(1,000)	0
Payments on finance lease obligations	(31)	(3)
Net cash provided by financing activities	8,730	8,846
Net decrease in cash, cash equivalents and restricted cash	(9,199)	(1,529)
Cash, cash equivalents and restricted cash at beginning of period	57,996	8,849
Cash, cash equivalents and restricted cash at end of period	48,797	7,320
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	539	763
Property, plant and equipment transferred to intangible assets	46	0
Purchase of property, plant and equipment in accounts payable	189	0
Purchase of intangible assets in accounts payable	294	0
Conversion of other liability amount into warrants	0	448
Lease liabilities arising from obtaining right of use assets:
Operating leases	437	491
Finance leases	$ 0	$ 51

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONSMedAvail Holdings, Inc., MedAvail, or the Company, a Delaware corporation is a telehealth-enabled pharmacy technology company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. MedAvail's principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counselling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. MedAvail also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited consolidated condensed financial statements as of June 30, 2021 and for the three and six months ended June 30, 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2020 was derived from the Company's audited consolidated condensed financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which includes normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 31, 2021, or the 2020 Form 10-K. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU will be effective beginning in the first quarter of our fiscal year 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated condensed financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its early adoption of the new standard on January 1, 2021. The adoption of ASU 2020-06 did not result in a material change to our consolidated condensed financial statements. There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 58,518 November 18, 2020 May 10, 2021 During the three and six months ended June 30, 2021 and 2020, there was no potential dilution from stock options or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020. The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended Six Months Ended (In thousands, except share and per share amounts) June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Net loss - basic and diluted $ (10,464) $ (6,536) $ (19,916) $ (12,226) Weighted average shares - basic and diluted 32,546,395 1,953,049 32,493,468 1,880,577 Net loss per share - basic and diluted $ (0.32) $ (3.35) $ (0.61) $ (6.50) As of June 30, 2021 and 2020, there were 2.1 million and 3.1 million, respectively, of option awards outstanding that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (In thousands) June 30, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 48,735 $ 48,735 $ — $ — Restricted cash 62 62 — — Total assets $ 48,797 $ 48,797 $ — $ — Fair Value Hierarchy (In thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ —

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Inventories The following table presents detail of inventory balances: June 30, December 31, (In thousands) 2021 2020 Inventories: MedCenter hardware $ 1,330 $ 1,655 Pharmacy 1,375 837 Spare parts 466 325 Total inventories $ 3,171 $ 2,817 Pharmacy inventory was recognized in pharmacy and hardware cost of sales at $4.1 million and $1.6 million during the three months ended June 30, 2021 and 2020, respectively, and $7.2 million and $2.9 million during the six months ended June 30, 2021 and 2020, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of sales at $0.2 million and $0.1 million during the three months ended June 30, 2021 and 2020, respectively, and $0.4 million and $0.1 million during the six months ended June 30, 2021 and 2020, respectively. Property, plant and equipment The following tables present property, plant and equipment balances: Estimated useful lives June 30, December 31, (In thousands) 2021 2020 Property, plant and equipment: MedCenter equipment 5 years $ 4,808 $ 4,622 IT equipment 1 - 3 years 2,239 1,999 Leasehold improvements lesser of useful life or term of lease 820 799 General plant and equipment 5 - 8 years 369 353 Office furniture and equipment 5 - 8 years 352 329 Vehicles 5 years 54 54 Construction-in-process 696 90 Total historical cost 9,338 8,246 Accumulated depreciation (5,036) (4,451) Total property, plant and equipment, net $ 4,302 $ 3,795 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended June 30, 2021 and 2020, respectively, and $0.6 million and $0.5 million for the six months ended June 30, 2021 and 2020, respectively. Depreciation expense included in pharmacy and hardware cost of sales was $0.04 million and $0.05 million for the three months ended June 30, 2021 and 2020, respectively, and $0.09 million and $0.10 million for the six months ended June 30, 2021 and 2020, respectively. Intangible assets The following table presents intangible asset balances: June 30, December 31, (In thousands) 2021 2020 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 3,074 1,815 Website and mobile application 583 583 Total intangible assets 7,514 6,255 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,688) (1,588) Website and mobile application (583) (583) Total accumulated amortization (6,128) (6,028) Total intangible assets, net $ 1,386 $ 227 Amortization expense of intangible assets was $0.07 million and $0.02 million for the three months ended June 30, 2021 and 2020, respectively, and $0.10 million and $0.06 million for the six months ended June 30, 2021 and 2020, respectively, and are included in operating expenses. Software includes internal use software costs that are accounted for in accordance with ASC 350. Costs associated with application development are capitalized as intangible assets. All other costs including planning, training, and conceptual evaluation are expensed. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (In thousands) 2021 2020 Assets: Operating $ 1,180 $ 1,108 Finance 103 131 Total assets $ 1,283 $ 1,239 Liabilities: Operating: Current $ 497 $ 612 Long-term 761 572 Finance: Current 52 53 Long-term 52 79 Total liabilities $ 1,362 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, (In thousands) 2021 2020 Finance leases: Weighted-average remaining lease term (years) 2.0 2.4 Weighted-average discount rate 6.0 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 3.3 2.5 Weighted-average discount rate 6.0 % 6.0 % Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2021 $ 325 2022 408 2023 262 2024 204 2025 137 2026 59 Thereafter — Total lease payments 1,395 Less: present value discount (137) Total leases $ 1,258 Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2021 $ 27 2022 57 2023 27 2024 — 2025 — 2026 — Thereafter — Total finance lease payments 111 Less: imputed interest (7) Total leases $ 104 Operating lease expense was $0.2 million and $0.1 million for the three months ended June 30, 2021 and 2020, respectively, and $0.4 million and $0.3 million for the six months ended June 30, 2021 and 2020, respectively. The Company entered into or extended operating leases with commencement dates after June 30, 2021, with total preliminary initial right of use asset balances of $1.8 million.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances at June 30, 2021 and December 31, 2020: June 30, December 31, (In thousands) 2021 2020 Short-term note due May 2021 $ — $ 1,000 Short-term note due November 2021 1,000 1,000 PPP loan — 161 Term loan 10,008 — Term loan issuance cost, net (594) — Total debt, net 10,414 2,161 Less short term debt (1,000) (2,161) Long-term debt, net $ 9,414 $ — Term loan Short-term notes The notes do not accrue interest and may be repaid early without penalty. On May 14, 2021 the Company repaid $1.0 million on the Short-term note in accordance with the maturity schedule. PPP loan MedAvail received forgiveness approval of the loan on March 30, 2021 in accordance with the terms of the CARES Act. Term loan On June 7, 2021, the Company entered into a Loan and Security Agreement, or the Loan Agreement, with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., pursuant to which we borrowed $10.0 million in aggregate initial term loans, or the Initial Loans. The Company may borrow up to an additional $20.0 million in aggregate term loans (or, together with the Initial Loans, the Loans) on or before April 30, 2022, subject to no material adverse change or event of default (each as defined in the Loan Agreement) having occurred and continuing. The Loans and the Company's obligations under the Loan Agreement are guaranteed by certain of our subsidiaries and are secured by substantially all of the assets of the Company and its subsidiary guarantors. The Loans mature on April 1, 2026. Principal repayment will commence on May 1, 2024 in equal monthly installments of the outstanding Loan balance through the maturity date. The Loans bear interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (7.25% at June 30, 2021). The Company may elect to prepay the Loans, in whole but not in part, at any time. If the Company elects to voluntarily prepay the Loans before the scheduled maturity date, the Company is required to pay the lenders a prepayment premium, equal to 3.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2022, 2.0% of the outstanding principal balance if the prepayment occurs on or before June 7, 2023, or 1.0% for a prepayment made after June 7, 2023, but before the scheduled maturity date. A prepayment premium is also applicable to a mandatory prepayment of the Loans upon an acceleration of the Loans. Upon a voluntary or mandatory prepayment of the Loans, the Company is also required to pay the lenders’ expenses and all accrued but unpaid interest on the Loans through the prepayment date. A final payment fee equal to 4.75% of the original principal amount of the Loans advanced will be due at the earlier of the maturity date, acceleration of the Loans, or a voluntary or mandatory prepayment of the Loans. The final payment fee is accreted to the Loan balance over the loan term using the effective interest method. The Loan Agreement includes customary representations and covenants that, subject to exceptions and qualifications, restrict the Company's ability to do the following things: engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; engage in businesses that are not related to existing business; add or change business locations; incur additional indebtedness; incur additional liens; make loans and investments; declare dividends or redeem or repurchase equity interests; and make certain amendments or payments in respect of any subordinated debt. In addition, the Loan Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, maintenance of our bank accounts, protection of our intellectual property, reporting requirements, compliance with applicable laws and regulations, and formation or acquisition of new subsidiaries. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and payable and may exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include, subject to grace periods in certain instances, payment defaults, breaches of covenants or representations and warranties, a material adverse change as defined in the Loan Agreement and with respect to certain governmental approvals, material judgments and attachments, cross defaults with certain other material indebtedness, bankruptcy and insolvency events with respect to the Company and its subsidiaries, and delisting of the Company's shares from NASDAQ. Loan issuance costs of $0.6 million are included in long term debt and are amortized to interest expense over the loan term using the effective interest method.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company did not incur income tax expense for the three and six months ended June 30, 2021, respectively, due to ongoing losses. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of June 30, 2021, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties. MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is required.

SHARE-BASED COMPENSATION EXPENS

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SHARE-BASED COMPENSATION EXPENSE AND WARRANTS	SHARE-BASED COMPENSATION AND WARRANTS Share-based compensation The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Share-based compensation $ 323 $ 86 $ 583 $ 170 The share-based compensation expense for the three and six months ended June 30, 2021, included $7 thousand from 2020 ESPP expense. Expense remaining to be recognized for unvested awards from the 2012, 2018, and 2020 plans as of June 30, 2021 was $3.0 million, which will be recognized on a weighted average basis over the next 2.9 years. The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2021: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,439,020 $ 1.59 $ 0.77 $ 32,791 Granted 315,974 13.70 8.04 — Exercised/Released (144,101) 1.71 $ 14.66 0.85 1,866 Cancelled/Forfeited (1,909) 1.68 0.84 24 Outstanding, end of period 2,608,984 $ 3.07 $ 1.34 7.97 $ 24,474 Vested and exercisable, end of the period 1,786,584 1.93 0.79 7.57 18,494 Vested and unvested exercisable, end of the period 1,786,584 1.93 0.79 7.57 18,494 Vested and expected to vest, end of the period 2,528,947 2.89 1.30 7.93 24,089 During the six months ended June 30, 2021, the Company granted approximately 89,974 restricted stock units or RSUs to employees with a weighted average fair value of $13.72 per RSU and total aggregate intrinsic value of $1.2 million. None of the RSUs were vested as of June 30, 2021, and they had a weighted average remaining contractual life of 9.8 years. As of June 30, 2021 and December 31, 2020, there was an aggregate of 4.7 million and 5.0 million shares of common stock, respectively, available for grant under the 2020 Plan. Warrants During the six months ended June 30, 2021 no warrants were issued. During the six months ended June 30, 2021, warrants were exercised in exchange for issuing 623,613 shares of the Company’s common stock with total cash proceeds of $124 thousand. Warrants exercised during the six months ended June 30, 2021, included 565,496 held by related parties (investors), with 626,339 related party warrants outstanding as of June 30, 2021.

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTING Operating segments are the individual operations that the chief operating decision maker ("CODM"), who is our chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail pharmacy services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy sales revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The pharmacy technology segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. The following table presents sales and costs of sales by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 4,494 $ — $ 4,494 Hardware — 123 123 Subscription sales — 108 108 Total pharmacy and hardware sales 4,494 231 4,725 Service sales: Software integration — — — Software — 41 41 Maintenance and support — 40 40 Installation — 12 12 Professional services and other — 212 212 Total service sales — 305 305 Total sales 4,494 536 5,030 Cost of sales 4,435 422 4,857 Gross profit $ 59 $ 114 $ 173 Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 1,713 $ — $ 1,713 Hardware — 423 423 Subscription sales — 123 123 Total pharmacy and hardware sales 1,713 546 2,259 Service sales: Software — 10 10 Maintenance and support — 13 13 Installation — 28 28 Professional services and other — 1 1 Total service sales — 52 52 Total sales 1,713 598 2,311 Cost of sales 1,679 186 1,865 Gross profit $ 34 $ 412 $ 446 Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 7,912 $ — $ 7,912 Hardware — 364 364 Subscription sales — 230 230 Total pharmacy and hardware sales 7,912 594 8,506 Service sales: Software — 74 74 Maintenance and support — 71 71 Installation — 28 28 Professional services and other — 378 378 Total service sales — 551 551 Total sales 7,912 1,145 9,057 Cost of sales 7,764 800 8,564 Gross profit $ 148 $ 345 $ 493 Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 3,010 $ — $ 3,010 Hardware — 423 423 Subscription sales — 228 228 Total pharmacy and hardware sales 3,010 651 3,661 Service sales: Software — 10 10 Maintenance and support — 23 23 Installation — 28 28 Professional services and other — 1 1 Total service sales — 62 62 Total sales 3,010 713 3,723 Cost of sales 3,017 280 3,297 Gross profit $ (7) $ 433 $ 426 The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total June 30, 2021 Assets $ 8,528 $ 4,407 $ 48,315 $ 61,250 Liabilities $ 4,205 $ 3,713 $ 11,233 $ 19,151 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: June 30, December 31, 2021 2020 Long-lived assets: United States $ 5,391 $ 4,533 Canada 194 501 Total long-lived assets $ 5,585 $ 5,034

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated condensed financial statements as of June 30, 2021 and for the three and six months ended June 30, 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2020 was derived from the Company's audited consolidated condensed financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which includes normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2020 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 31, 2021, or the 2020 Form 10-K. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary.
Principles of consolidation	Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Recently Adopted Accounting Standards	Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures. Recently Adopted Accounting Standards Simplifying the Accounting for Income Taxes In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU will be effective beginning in the first quarter of our fiscal year 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated condensed financial statements. Debt with Conversion and Other Options In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its early adoption of the new standard on January 1, 2021. The adoption of ASU 2020-06 did not result in a material change to our consolidated condensed financial statements. There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 58,518 November 18, 2020 May 10, 2021
Schedule of Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share. Three Months Ended Six Months Ended (In thousands, except share and per share amounts) June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Net loss - basic and diluted $ (10,464) $ (6,536) $ (19,916) $ (12,226) Weighted average shares - basic and diluted 32,546,395 1,953,049 32,493,468 1,880,577 Net loss per share - basic and diluted $ (0.32) $ (3.35) $ (0.61) $ (6.50)

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (In thousands) June 30, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 48,735 $ 48,735 $ — $ — Restricted cash 62 62 — — Total assets $ 48,797 $ 48,797 $ — $ — Fair Value Hierarchy (In thousands) December 31, 2020 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 57,936 $ 57,936 $ — $ — Restricted cash 60 60 — — Total assets $ 57,996 $ 57,996 $ — $ —

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: June 30, December 31, (In thousands) 2021 2020 Inventories: MedCenter hardware $ 1,330 $ 1,655 Pharmacy 1,375 837 Spare parts 466 325 Total inventories $ 3,171 $ 2,817
Schedule of Property, Plant and Equipment and Useful Lives	The following tables present property, plant and equipment balances: Estimated useful lives June 30, December 31, (In thousands) 2021 2020 Property, plant and equipment: MedCenter equipment 5 years $ 4,808 $ 4,622 IT equipment 1 - 3 years 2,239 1,999 Leasehold improvements lesser of useful life or term of lease 820 799 General plant and equipment 5 - 8 years 369 353 Office furniture and equipment 5 - 8 years 352 329 Vehicles 5 years 54 54 Construction-in-process 696 90 Total historical cost 9,338 8,246 Accumulated depreciation (5,036) (4,451) Total property, plant and equipment, net $ 4,302 $ 3,795
Schedule of Finite-Lived Intangible Assets	The following table presents intangible asset balances: June 30, December 31, (In thousands) 2021 2020 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 3,074 1,815 Website and mobile application 583 583 Total intangible assets 7,514 6,255 Accumulated amortization: Intellectual property (3,857) (3,857) Software (1,688) (1,588) Website and mobile application (583) (583) Total accumulated amortization (6,128) (6,028) Total intangible assets, net $ 1,386 $ 227
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (In thousands) 2021 2020 Assets: Operating $ 1,180 $ 1,108 Finance 103 131 Total assets $ 1,283 $ 1,239 Liabilities: Operating: Current $ 497 $ 612 Long-term 761 572 Finance: Current 52 53 Long-term 52 79 Total liabilities $ 1,362 $ 1,316 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, (In thousands) 2021 2020 Finance leases: Weighted-average remaining lease term (years) 2.0 2.4 Weighted-average discount rate 6.0 % 6.0 % Operating leases: Weighted-average remaining lease term (years) 3.3 2.5 Weighted-average discount rate 6.0 % 6.0 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2021 $ 325 2022 408 2023 262 2024 204 2025 137 2026 59 Thereafter — Total lease payments 1,395 Less: present value discount (137) Total leases $ 1,258
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2021 $ 27 2022 57 2023 27 2024 — 2025 — 2026 — Thereafter — Total finance lease payments 111 Less: imputed interest (7) Total leases $ 104

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances at June 30, 2021 and December 31, 2020: June 30, December 31, (In thousands) 2021 2020 Short-term note due May 2021 $ — $ 1,000 Short-term note due November 2021 1,000 1,000 PPP loan — 161 Term loan 10,008 — Term loan issuance cost, net (594) — Total debt, net 10,414 2,161 Less short term debt (1,000) (2,161) Long-term debt, net $ 9,414 $ —

SHARE-BASED COMPENSATION EXPE_2

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Schedule of MedAvail Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation, in thousands: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Share-based compensation $ 323 $ 86 $ 583 $ 170
Share-based Payment Arrangement, Option, Activity	The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2021: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,439,020 $ 1.59 $ 0.77 $ 32,791 Granted 315,974 13.70 8.04 — Exercised/Released (144,101) 1.71 $ 14.66 0.85 1,866 Cancelled/Forfeited (1,909) 1.68 0.84 24 Outstanding, end of period 2,608,984 $ 3.07 $ 1.34 7.97 $ 24,474 Vested and exercisable, end of the period 1,786,584 1.93 0.79 7.57 18,494 Vested and unvested exercisable, end of the period 1,786,584 1.93 0.79 7.57 18,494 Vested and expected to vest, end of the period 2,528,947 2.89 1.30 7.93 24,089

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following table presents sales and costs of sales by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 4,494 $ — $ 4,494 Hardware — 123 123 Subscription sales — 108 108 Total pharmacy and hardware sales 4,494 231 4,725 Service sales: Software integration — — — Software — 41 41 Maintenance and support — 40 40 Installation — 12 12 Professional services and other — 212 212 Total service sales — 305 305 Total sales 4,494 536 5,030 Cost of sales 4,435 422 4,857 Gross profit $ 59 $ 114 $ 173 Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 1,713 $ — $ 1,713 Hardware — 423 423 Subscription sales — 123 123 Total pharmacy and hardware sales 1,713 546 2,259 Service sales: Software — 10 10 Maintenance and support — 13 13 Installation — 28 28 Professional services and other — 1 1 Total service sales — 52 52 Total sales 1,713 598 2,311 Cost of sales 1,679 186 1,865 Gross profit $ 34 $ 412 $ 446 Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2021 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 7,912 $ — $ 7,912 Hardware — 364 364 Subscription sales — 230 230 Total pharmacy and hardware sales 7,912 594 8,506 Service sales: Software — 74 74 Maintenance and support — 71 71 Installation — 28 28 Professional services and other — 378 378 Total service sales — 551 551 Total sales 7,912 1,145 9,057 Cost of sales 7,764 800 8,564 Gross profit $ 148 $ 345 $ 493 Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2020 Sales: Pharmacy and hardware sales: Retail pharmacy sales $ 3,010 $ — $ 3,010 Hardware — 423 423 Subscription sales — 228 228 Total pharmacy and hardware sales 3,010 651 3,661 Service sales: Software — 10 10 Maintenance and support — 23 23 Installation — 28 28 Professional services and other — 1 1 Total service sales — 62 62 Total sales 3,010 713 3,723 Cost of sales 3,017 280 3,297 Gross profit $ (7) $ 433 $ 426
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment, in thousands: Retail Pharmacy Services Pharmacy Technology Corporate Total June 30, 2021 Assets $ 8,528 $ 4,407 $ 48,315 $ 61,250 Liabilities $ 4,205 $ 3,713 $ 11,233 $ 19,151 December 31, 2020 Assets $ 6,012 $ 5,547 $ 57,772 $ 69,331 Liabilities $ 2,203 $ 3,422 $ 2,639 $ 8,264 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets, in thousands: June 30, December 31, 2021 2020 Long-lived assets: United States $ 5,391 $ 4,533 Canada 194 501 Total long-lived assets $ 5,585 $ 5,034

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	6 Months Ended
	Jun. 30, 2021shares
Warrants Issued May 9, 2018
Common
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Common
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Common
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Common
Warrants (in shares)	58,518

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) shares in Millions	Nov. 17, 2020	Jun. 30, 2021shares	Jun. 30, 2020shares
Earnings Per Share [Abstract]
Stock split, conversion ratio	1.26
Potentially dilutive option awards excluded from earnings per share calculation (in shares)		2.1	3.1

EARNINGS (LOSS) PER SHARE - Cal

EARNINGS (LOSS) PER SHARE - Calculation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss - basic and diluted	$ (10,464)	$ (6,536)	$ (19,916)	$ (12,226)
Weighted average shares outstanding - basic (in shares)	32,546,395	1,953,049	32,493,468	1,880,577
Weighted average shares outstanding - diluted (in shares)	32,546,395	1,953,049	32,493,468	1,880,577
Net loss per share - basic (in USD per share)	$ (0.32)	$ (3.35)	$ (0.61)	$ (6.50)
Net loss per share - diluted (in USD per share)	$ (0.32)	$ (3.35)	$ (0.61)	$ (6.50)

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 48,735	$ 57,936
Restricted cash	62	60
Total assets	48,797	57,996
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		57,936
Restricted cash	62	60
Total assets	48,797	57,996
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 1,330	$ 1,655
Pharmacy	1,375	837
Spare parts	466	325
Total inventories	$ 3,171	$ 2,817

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Inventory [Line Items]
Depreciation of property, plant, and equipment	$ 300	$ 300	$ 586	$ 463
Depreciation included in cost of sales	40	50	90	100
Amortization of intangible assets	70	20	100	60
Operating lease, expense	200	100	400	300
Operating lease, not yet commenced, initial right-of-use asset	1,800		1,800
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	4,100	1,600	7,200	2,900
MedCenter
Inventory [Line Items]
Inventory recognized as cost of sales	$ 200	$ 100	$ 400	$ 100

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Historical cost	$ 9,338	$ 8,246
Accumulated depreciation	(5,036)	(4,451)
Property, plant and equipment, net	$ 4,302	3,795
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Historical cost	$ 4,808	4,622
IT equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 2,239	1,999
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Historical cost	$ 820	799
General plant and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 369	353
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 352	329
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives of fixed assets	5 years
Historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Historical cost	$ 696	$ 90

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 7,514	$ 6,255
Accumulated amortization	(6,128)	(6,028)
Total intangible assets, net	1,386	227
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,074	1,815
Accumulated amortization	(1,688)	(1,588)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Total assets	Total assets
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Total assets	Total assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of lease obligations	Current portion of lease obligations
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term portion of lease obligations	Long-term portion of lease obligations
Assets
Operating	$ 1,180	$ 1,108
Finance	103	131
Total assets	1,283	1,239
Operating:
Current	497	612
Long-term	761	572
Finance:
Current	52	53
Long-term	52	79
Total liabilities	$ 1,362	$ 1,316

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Jun. 30, 2021	Dec. 31, 2020
Finance leases:
Weighted-average remaining lease term (years)	2 years	2 years 4 months 24 days
Weighted-average discount rate	6.00%	6.00%
Operating leases:
Weighted-average remaining lease term (years)	3 years 3 months 18 days	2 years 6 months
Weighted-average discount rate	6.00%	6.00%

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2021	$ 325
2022	408
2023	262
2024	204
2025	137
2026	59
Thereafter	0
Total lease payments	1,395
Less: present value discount	(137)
Total leases	$ 1,258

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2021	$ 27
2022	57
2023	27
2024	0
2025	0
2026	0
Thereafter	0
Total finance lease payments	111
Less: imputed interest	(7)
Total leases	$ 104

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt, net	$ 10,414	$ 2,161
Less short term debt	(1,000)	(2,161)
Long-term debt, net	9,414	0
Short-term note due May 2021 | Other Payables
Debt Instrument [Line Items]
Short-term notes	0	1,000
Short-term note due November 2021 | Other Payables
Debt Instrument [Line Items]
Short-term notes	1,000	1,000
PPP loan | Notes Payable to Banks
Debt Instrument [Line Items]
Long-term loans	0	161
Term loan | Secured Debt
Debt Instrument [Line Items]
Long-term loans	10,008	0
Term loan issuance cost, net	$ (594)	$ 0

DEBT - Narrative (Details)

DEBT - Narrative (Details) - USD ($)	Jun. 07, 2021	May 14, 2021	Jun. 30, 2021	Jun. 30, 2020
Debt Instrument [Line Items]
Repayment of debt			$ 1,000,000	$ 0
Short-term note due May 2021 | Other Payables
Debt Instrument [Line Items]
Repayment of debt		$ 1,000,000
Term loan | Secured Debt
Debt Instrument [Line Items]
Principal amount	$ 10,000,000
Additional borrowing capacity available	$ 20,000,000
Debt instrument, interest rate floor	7.25%
Interest rate at end of period			7.25%
Debt final payment fee, percentage	4.75%
Debt issuance costs, gross	$ 600,000
Term loan | Secured Debt | Prepayment before June 7, 2022
Debt Instrument [Line Items]
Debt prepayment fee, percentage	3.00%
Term loan | Secured Debt | Prepayment before June 7, 2023
Debt Instrument [Line Items]
Debt prepayment fee, percentage	2.00%
Term loan | Secured Debt | Prepayment after June 7, 2023
Debt Instrument [Line Items]
Debt prepayment fee, percentage	1.00%
Term loan | Secured Debt | Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4.00%

SHARE-BASED COMPENSATION EXPE_3

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Equity [Abstract]
Share-based compensation	$ 323	$ 86	$ 583	$ 170

SHARE-BASED COMPENSATION EXPE_4

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 323	$ 86	$ 583	$ 170
Expense remaining to be recognized	$ 3,000		$ 3,000
Weighted average recognition period (in years)			2 years 10 months 24 days
Aggregate shares on common stock available for grant (in shares)	4,700,000		4,700,000		5,000,000
Warrants issued during the period (in shares)			0
Proceeds from warrant exercises			$ 124
Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)	620,659		623,613
Investors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants (in shares)	626,339		626,339
Investors | Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of warrants (in shares)			565,496
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 7		$ 7
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			89,974
Grant date fair value of awards granted (in USD per share)			$ 13.72
Aggregate intrinsic value of awards granted			$ 1,200
Number of vested awards (in shares)	0		0
Weighted average remaining contractual life			9 years 9 months 18 days

SHARE-BASED COMPENSATION EXPE_5

SHARE-BASED COMPENSATION EXPENSE AND WARRANTS - Option Activity (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021
Number of Awards
Outstanding awards at beginning of period (in shares)	2,439,020
Granted (in shares)	315,974
Shares issued for options exercises (in shares)	(144,101)
Awards cancelled/forfeited (in shares)	(1,909)
Outstanding awards at end of period (in shares)	2,608,984
Awards vested and exercisable (in shares)	1,786,584
Awards vested and unvested exercisable (in shares)	1,786,584
Awards vested and expected to vest (in shares)	2,528,947
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)	$ 1.59
Weighted average exercise price of awards granted (in USD per share)	13.70
Weighted average exercise price of awards exercised/released (in USD per share)	1.71
Weighted average exercise price of awards cancelled/forfeited (in USD per share)	1.68
Weighted average exercise price of awards outstanding at end of period (in USD per share)	3.07
Weighted average exercise price of awards vested and exercisable (in USD per share)	1.93
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)	1.93
Weighted average exercise price of awards vested and expected to vest (in USD per share)	2.89
Weighted average share price on date of exercise (in USD per share)	14.66
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	0.77
Grant date fair value of options granted (in USD per share)	8.04
Weighted average fair value of awards exercised/released (in USD per share)	0.85
Weighted average fair value of awards cancelled/forfeited (in USD per share)	0.84
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.34
Weighted average fair value of awards vested and exercisable (in USD per share)	0.79
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0.79
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.30
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period	7 years 11 months 19 days
Vested and exercisable, end of the period	7 years 6 months 25 days
Vested and unvested exercisable, end of the period	7 years 6 months 25 days
Vested and expected to vest, end of the period	7 years 11 months 4 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period	$ 32,791,000
Aggregate intrinsic value of awards granted	0
Aggregate intrinsic value of awards exercised/released	1,866,000
Aggregate intrinsic value of awards cancelled/forfeited	24,000
Aggregate intrinsic value of awards outstanding at end of period	24,474,000
Aggregate intrinsic value of awards vested and exercisable	18,494,000
Aggregate intrinsic value of awards vested and unvested exercisable	18,494,000
Aggregate intrinsic value of awards vested and expected to vest	$ 24,089,000

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details)	6 Months Ended
	Jun. 30, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 5,030	$ 2,311	$ 9,057	$ 3,723
Total cost of sales	4,857	1,865	8,564	3,297
Gross profit	173	446	493	426
Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	4,494	1,713	7,912	3,010
Total cost of sales	4,435	1,679	7,764	3,017
Gross profit	59	34	148	(7)
Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	536	598	1,145	713
Total cost of sales	422	186	800	280
Gross profit	114	412	345	433
Retail pharmacy sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	4,494	1,713	7,912	3,010
Retail pharmacy sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	4,494	1,713	7,912	3,010
Retail pharmacy sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	123	423	364	423
Hardware | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Hardware | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	123	423	364	423
Subscription sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108	123	230	228
Subscription sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Subscription sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108	123	230	228
Pharmacy and hardware sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	4,725	2,259	8,506	3,661
Total cost of sales	4,679	1,826	8,205	3,211
Pharmacy and hardware sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	4,494	1,713	7,912	3,010
Pharmacy and hardware sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	231	546	594	651
Software integration
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales			0
Software integration | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales			0
Software integration | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales			0
Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	41	10	74	10
Software | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Software | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	41	10	74	10
Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	40	13	71	23
Maintenance and support | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Maintenance and support | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	40	13	71	23
Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	12	28	28	28
Installation | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Installation | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	12	28	28	28
Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	212	1	378	1
Professional services and other | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Professional services and other | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	212	1	378	1
Service sales
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	305	52	551	62
Total cost of sales	178	39	359	86
Service sales | Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	0	0	0	0
Service sales | Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 305	$ 52	$ 551	$ 62

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 61,250	$ 69,331
Total liabilities	19,151	8,264
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	8,528	6,012
Total liabilities	4,205	2,203
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	4,407	5,547
Total liabilities	3,713	3,422
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	48,315	57,772
Total liabilities	$ 11,233	$ 2,639

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 5,585	$ 5,034
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	5,391	4,533
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived assets	$ 194	$ 501